Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2014 1
2019 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Karvouni M, Vidal-Manrique M, Susek KH, Hussain A, Gilljam M, Zhang Y, Gray JD, Lund J, Kaufmann G, Ljunggren HG, Ji H, Lundqvist A, Wagner AK, Guo W, Alici E. Karvouni M, et al. Among authors: gilljam m. Cytotherapy. 2023 Jul;25(7):763-772. doi: 10.1016/j.jcyt.2023.03.006. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055320 Free article.
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Susek KH, Schwietzer YA, Karvouni M, Gilljam M, Keszei M, Hussain A, Lund J, Kashif M, Lundqvist A, Ljunggren HG, Nahi H, Wagner AK, Alici E. Susek KH, et al. Among authors: gilljam m. Cancer Immunol Immunother. 2023 May;72(5):1153-1167. doi: 10.1007/s00262-022-03317-y. Epub 2022 Nov 10. Cancer Immunol Immunother. 2023. PMID: 36355079 Free PMC article.
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.
Nahi H, Chrobok M, Meinke S, Gran C, Marquardt N, Afram G, Sutlu T, Gilljam M, Stellan B, Wagner AK, Blomberg P, Holmqvist PH, Walther-Jallow L, Mellström K, Liwing J, Gustafsson C, Månsson R, Klimkowska M, Gahrton G, Lund J, Ljungman P, Ljunggren HG, Alici E. Nahi H, et al. Among authors: gilljam m. Cell Rep Med. 2022 Jan 28;3(2):100508. doi: 10.1016/j.xcrm.2022.100508. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35243416 Free PMC article.
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells.
Chrobok M, Dahlberg CIM, Sayitoglu EC, Beljanski V, Nahi H, Gilljam M, Stellan B, Sutlu T, Duru AD, Alici E. Chrobok M, et al. Among authors: gilljam m. Cancers (Basel). 2019 Jan 10;11(1):69. doi: 10.3390/cancers11010069. Cancers (Basel). 2019. PMID: 30634595 Free PMC article.
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Björkström NK, Söderdahl G, Cederlund K, Kimby E, Aschan J, Ringdén O, Ljunggren HG, Dilber MS. Barkholt L, et al. Among authors: gilljam m. Immunotherapy. 2009 Sep;1(5):753-64. doi: 10.2217/imt.09.47. Immunotherapy. 2009. PMID: 20636021 Clinical Trial.
Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data.
Martins JP, Santos JM, de Almeida JM, Filipe MA, de Almeida MV, Almeida SC, Água-Doce A, Varela A, Gilljam M, Stellan B, Pohl S, Dittmar K, Lindenmaier W, Alici E, Graça L, Cruz PE, Cruz HJ, Bárcia RN. Martins JP, et al. Among authors: gilljam m. Stem Cell Res Ther. 2014 Jan 17;5(1):9. doi: 10.1186/scrt398. Stem Cell Res Ther. 2014. PMID: 24438697 Free PMC article.